Status:
COMPLETED
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
Lead Sponsor:
GlaxoSmithKline
Conditions:
Ataxia
Eligibility:
All Genders
Brief Summary
The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of fondaparinux injection in patients with venous thromboembolism (VTE). ("Arixtra" i...
Eligibility Criteria
Inclusion
- Patients with acute pulmonary thromboembolism or acute deep venous thrombosis
- Fondaparinux injection must be prescribed for the first time
Exclusion
- Not applicable
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01428531
Start Date
January 1 2012
End Date
June 1 2015
Last Update
July 15 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.